Brian Mckeon Purchases 10,000 Shares of DENTSPLY SIRONA (NASDAQ:XRAY) Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Brian Mckeon bought 10,000 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was bought at an average cost of $10.12 per share, with a total value of $101,200.00. Following the transaction, the director directly owned 10,000 shares of the company’s stock, valued at approximately $101,200. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

DENTSPLY SIRONA Stock Up 0.5%

Shares of NASDAQ XRAY traded up $0.05 on Monday, hitting $10.14. The company had a trading volume of 2,937,234 shares, compared to its average volume of 4,807,820. DENTSPLY SIRONA Inc. has a 12-month low of $9.40 and a 12-month high of $17.09. The business has a 50 day moving average of $10.98 and a two-hundred day moving average of $11.71. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. The firm has a market capitalization of $2.03 billion, a P/E ratio of -3.22, a PEG ratio of 1.20 and a beta of 0.89.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The company had revenue of $880.00 million during the quarter, compared to analysts’ expectations of $841.80 million. During the same period in the previous year, the company earned $0.43 EPS. DENTSPLY SIRONA’s quarterly revenue was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts forecast that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on XRAY. Zacks Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Bank of America raised DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and upped their target price for the stock from $13.00 to $17.00 in a research report on Thursday, February 19th. Wells Fargo & Company upped their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. UBS Group decreased their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Mizuho cut their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $13.55.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of institutional investors have recently made changes to their positions in XRAY. First Eagle Investment Management LLC boosted its position in shares of DENTSPLY SIRONA by 3.2% during the fourth quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after buying an additional 458,744 shares during the period. Sound Income Strategies LLC increased its position in DENTSPLY SIRONA by 32.3% in the 4th quarter. Sound Income Strategies LLC now owns 611,308 shares of the medical instruments supplier’s stock valued at $7,464,000 after acquiring an additional 149,384 shares during the period. Skba Capital Management LLC raised its stake in DENTSPLY SIRONA by 14.3% during the 3rd quarter. Skba Capital Management LLC now owns 1,140,430 shares of the medical instruments supplier’s stock valued at $14,472,000 after acquiring an additional 142,900 shares in the last quarter. Invenomic Capital Management LP raised its stake in DENTSPLY SIRONA by 48.7% during the 3rd quarter. Invenomic Capital Management LP now owns 4,351,199 shares of the medical instruments supplier’s stock valued at $55,217,000 after acquiring an additional 1,425,637 shares in the last quarter. Finally, Crawford Investment Counsel Inc. bought a new stake in DENTSPLY SIRONA during the 3rd quarter valued at $1,104,000. 95.70% of the stock is currently owned by institutional investors.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.